Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Rebecca Taub Sells 647 Shares

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Rebecca Taub sold 647 shares of Madrigal Pharmaceuticals stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $492.42, for a total value of $318,595.74. Following the sale, the director owned 452,704 shares of the company’s stock, valued at approximately $222,920,503.68. This represents a 0.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Rebecca Taub also recently made the following trade(s):

• On Tuesday, January 20th, Rebecca Taub sold 2,238 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $490.77, for a total transaction of $1,098,343.26.
• On Friday, January 9th, Rebecca Taub sold 18,410 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $522.40, for a total transaction of $9,617,384.00.
• On Friday, January 9th, Rebecca Taub sold 240 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $550.33, for a total transaction of $132,079.20.
• On Wednesday, December 10th, Rebecca Taub sold 18,650 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $552.15, for a total transaction of $10,297,597.50.

Madrigal Pharmaceuticals Trading Up 3.9%

MDGL stock traded up $18.72 during midday trading on Monday, hitting $499.17. The stock had a trading volume of 336,495 shares, compared to its average volume of 364,506. The firm has a market cap of $11.34 billion, a PE ratio of -38.37, a price-to-earnings-growth ratio of 4.66 and a beta of -1.00. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.44 and a quick ratio of 3.26. Madrigal Pharmaceuticals, Inc. has a 12-month low of $265.00 and a 12-month high of $615.00. The company’s 50-day moving average price is $559.15 and its 200 day moving average price is $460.34.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative return on equity of 41.50% and a negative net margin of 39.04%. On average, equities research analysts predict that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of MDGL. AlphaQuest LLC increased its position in shares of Madrigal Pharmaceuticals by 412.5% in the second quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 66 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new position in shares of Madrigal Pharmaceuticals during the 4th quarter valued at $29,000. Mather Group LLC. purchased a new stake in Madrigal Pharmaceuticals during the 3rd quarter worth $33,000. Global Retirement Partners LLC increased its holdings in Madrigal Pharmaceuticals by 221.7% in the 3rd quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 51 shares in the last quarter. Finally, First Horizon Corp acquired a new stake in Madrigal Pharmaceuticals in the 3rd quarter valued at $34,000. 98.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have commented on MDGL shares. Oppenheimer upped their price objective on shares of Madrigal Pharmaceuticals from $600.00 to $650.00 and gave the company an “outperform” rating in a research note on Thursday, November 20th. B. Riley boosted their target price on shares of Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Truist Financial increased their price target on shares of Madrigal Pharmaceuticals from $580.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, November 19th. Citigroup reissued an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, January 20th. Finally, Wolfe Research set a $579.00 price objective on Madrigal Pharmaceuticals in a report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $632.64.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.